Lupin receives US FDA approval for Cefadroxil capsules

New Delhi, May 31 (UNI) Lupin Ltd today said it has received approval from the US Food and Drug Administration (FDA) for it's Abbreviated New Drug Application (ANDA) for Cefadroxil Capsules (500mg) used for treating infections.

This approval augments the cephalosporin portfolio of the Company in the 8.7 billion dollar-broad spectrum antibiotic market in the US.

Cefadroxil is a broad spectrum antibiotic, used to treat various bacterial infections.

The capsules are the AB-rated generic equivalent of Warner Chilcott (erstwhile) Duricef capsules.

With this approval, Lupin now has 23 ANDAs approved by the US FDA.

UNI